Monument Therapeutics Partners with FNIH for Innovative Schizophrenia Treatment Clinical Trial Monument Therapeutics collaborates with the Foundation for NIH to explore a groundbreaking treatment for cognitive issues in schizophrenia, MT1988.

Monument Therapeutics Partners with FNIH for Innovative Schizophrenia Treatment Clinical Trial #United_Kingdom #Manchester #Monument_Therapeutics #FNIH #MT1988

Analysis of multiple MRI-based quantitative structural measurements of knee osteoarthritis in a case control study – association with pain and structural progression and comparison to semi-quantitativ... To use software-based magnetic resonance imaging (MRI) measures of multiple features of knee osteoarthritis (KOA) to predict radiographic and pain progression in persons with KOA, and compare to a stu...

New work w/ colleagues at #BWH in @oacjournal.bsky.social - Smith et al. Analysis of multiple MRI-based quantitative structural measurements of knee osteoarthritis in a case control study

Secondary analysis of #FNIH study using quantitative MRI biomarkers
www.oarsiopenjournal.com/article/S266...

AAV vectors trigger DNA damage response-dependent pro-inflammatory signalling in human iPSC-derived CNS models and mouse brain Nature Communications - Costa-Verdera et. al describe a mechanism by which AAV vector genomes activate P53-mediated signalling in CNS cells involving downstream STING activation and...

We are super excited to share our work on #InnateImmune sensing of #AAV 🦠🧬 in the 🧠, just out in @natcomms.nature.com ! 🤩

Huge congratulations to all the team and collaborators 💪🏻

And our funders 💰
@erc.europa.eu #FondazioneTelethon and #FNIH 🙏🏻

www.nature.com/articles/s41...

I’m delighted to share this short film highlighting the @FNIH_Org’s Accelerating Medicines Partnership® (AMP®) program. This video showcases the strengths of public-private partnerships and their impact over the past decade.

https://youtu.be/9glpzJM54K4?si=3GBco36ldx1_Kb6n via @YouTube

#FNIH

The AMP® SCZ (Accelerating Medicines Partnership® Schizophrenia) is a public-private partnership aimed at identifying biomarkers of schizophrenia to develop more effective treatments.

Watch here for an in-depth look: https://www.youtube.com/watch?v=MtS5f60SEcY

#FNIH #mentalhealth #research